Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TherVacB
- Development stage
- Phase 2
- Lead developer
- Helmholtz Zentrum München
- Modality
- Recombinant Proteins and Enzymes, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**TherVacB** is an investigational heterologous prime-boost therapeutic vaccine regimen for **chronic hepatitis B**. It uses protein-based priming with hepatitis B virus surface antigen and mosaic hepatitis B virus core antigen particles, followed by a modified vaccinia Ankara vector boost, MVA-HBVac, encoding hepatitis B virus core, surface, large surface, and polymerase antigens. The regimen is intended to overcome hepatitis B virus-specific immune tolerance by inducing neutralizing antibody responses and broad hepatitis B virus-specific CD4 and CD8 T-cell immunity in people with chronic infection. ([uke.de](https://www.uke.de/english/departments-institutes/institutes/infection-research-and-vaccine-development/clinical-trials/thervacb-study.html))
- Other names
- HEPLISAV B-Universitätsklinikum Hamburg-Eppendorf-chronic hepatitis BHeterologous protein prime/MVA boost therapeutic hepatitis B vaccine
02
Targets
HBc (Hepatitis B virus core protein)HBsAg (Hepatitis B surface antigen)HBsAg-specific BCR (HBsAg-specific B-cell receptor)HBV-specific TCR (Hepatitis B virus PreS2/core-specific T-cell receptor)
Beyond the preview
Go deeper on TherVacB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TherVacB.